Kremlin says technological differences with EMA on Russia's Sputnik V certification
The exterior of EMA, European Medicines Agency is seen in Amsterdam, Netherlands December 18, 2020. REUTERS/Piroschka van de Wouw/File Photo
Register now for FREE unlimited access to Reuters.com
MOSCOW, Oct 21 (Reuters) - The Kremlin on Thursday said there were technological differences between Moscow and the European Medicines Agency (EMA) regarding the completeness of paperwork submitted for the certification of Russia's Sputnik V vaccine.
The EU drug regulator is unlikely to decide whether to approve Sputnik V until at least the first quarter of 2022 because some data needed for the review was still missing, a source with knowledge of the matter told Reuters. read more
Register now for FREE unlimited access to Reuters.com
Our Standards: The Thomson Reuters Trust Principles.